Ersan Akkaya
Ersan Akkaya has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Damir Erkapic
Department of Cardiology and Electrophysiology, Jung Stilling Hospital Siegen, Germany
2 shared publicationsJohannes Rixe
Department of Cardiology and Electrophysiology, Jung Stilling Hospital Siegen, Germany
2 shared publicationsKorkut Sözener
Department of Cardiology and Electrophysiology, Jung Stilling Hospital Siegen, Germany
2 shared publicationsAlexander Berkowitsch
Department of Cardiology, Kerckhoff Heart Center, Benekestr. 2-8, 61231, Bad Nauheim, Germany
1 shared publicationAndreas Hain
Department of Cardiology, Kerckhoff Heart Center, Benekestr. 2-8, 61231, Bad Nauheim, Germany
1 shared publicationChristian Tanislav
Department of Geriatric Neurology, Jung Stilling Hospital Siegen, Germany
1 shared publication
Latest Publications
- 30 October 2019
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 109 (6) , 714-724
Left atrial roof ablation in patients with persistent atrial fibrillation using the second-generation cryoballoon: benefit or wasted time?
It is unknown whether left atrial (LA) roof ablation combined with pulmonary vein isolation (PVI) using a second-generation cryoballoon provides additional benefit beyond that of PVI alone in patients with persistent atrial fibrillation (AF). The aim of this study was to compare arrhythmia recurrence rates after PVI alone versus PVI plus LA roof ablation.
- 30 October 2019
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 109 (6) , 714-724
Left atrial roof ablation in patients with persistent atrial fibrillation using the second-generation cryoballoon: benefit or wasted time?
It is unknown whether left atrial (LA) roof ablation combined with pulmonary vein isolation (PVI) using a second-generation cryoballoon provides additional benefit beyond that of PVI alone in patients with persistent atrial fibrillation (AF). The aim of this study was to compare arrhythmia recurrence rates after PVI alone versus PVI plus LA roof ablation.
- 22 October 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (1) , 179-186
Venous access closure using a purse‐string suture without heparin antagonism or additional compression after MitraClip implantation
Objectives: This observational study was designed to analyze the safety and feasibility of percutaneous skin closure using a purse‐string suture (PSS) after MitraClip procedures.Methods: Forty‐one consecutive patients with severe mitral regurgitation who underwent MitraClip implantation from February 2018 to January 2019 at our institution received a PSS after percutaneous mitral valve repair before withdrawal of the 24‐French (Fr) sheath. Protamine was not administered after venous closure at procedure end. No compression therapy (e.g., compression bandage or pneumatic compression device) was used. Patients were on bed rest for 6 hrs prior to suture removal, which was accomplished 18–24 hrs after MitraClip implantation. We analyzed the occurrence of any vascular or thromboembolic complications during the hospital stay and until the 3‐month follow‐up.Results: The primary endpoint—any access‐related major complication—did not occur in any patients. None of the patients revealed a pseudoaneurysm or an arteriovenous fistula, a thromboembolic complication, or local stenosis related to the PSS closure. The secondary endpoint— minor access‐site vascular complications (hematoma)— was documented in six (14.6%) patients.Conclusions: Venous access‐site closure with a PSS without the need for protamine administration or compression therapy appears to be safe and feasible in patients undergoing MitraClip implantation with access via a 24‐Fr sheath.
- 22 October 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (1) , 179-186
Venous access closure using a purse‐string suture without heparin antagonism or additional compression after MitraClip implantation
Objectives: This observational study was designed to analyze the safety and feasibility of percutaneous skin closure using a purse‐string suture (PSS) after MitraClip procedures.Methods: Forty‐one consecutive patients with severe mitral regurgitation who underwent MitraClip implantation from February 2018 to January 2019 at our institution received a PSS after percutaneous mitral valve repair before withdrawal of the 24‐French (Fr) sheath. Protamine was not administered after venous closure at procedure end. No compression therapy (e.g., compression bandage or pneumatic compression device) was used. Patients were on bed rest for 6 hrs prior to suture removal, which was accomplished 18–24 hrs after MitraClip implantation. We analyzed the occurrence of any vascular or thromboembolic complications during the hospital stay and until the 3‐month follow‐up.Results: The primary endpoint—any access‐related major complication—did not occur in any patients. None of the patients revealed a pseudoaneurysm or an arteriovenous fistula, a thromboembolic complication, or local stenosis related to the PSS closure. The secondary endpoint— minor access‐site vascular complications (hematoma)— was documented in six (14.6%) patients.Conclusions: Venous access‐site closure with a PSS without the need for protamine administration or compression therapy appears to be safe and feasible in patients undergoing MitraClip implantation with access via a 24‐Fr sheath.
- Open Access
- 23 August 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (10) , 1903-1906
Successful cryoballoon ablation of a focal atrial tachycardia in a patient with situs inversus and dextrocardia
Cryoballoon ablation of an arrhythmogenic focus alongside a pulmonary vein as an alternative to radiofrequency ablation may be feasible and safe in patients with situs inversus and dextrocardia.
- 23 August 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (10) , 1903-1906
Open AccessSuccessful cryoballoon ablation of a focal atrial tachycardia in a patient with situs inversus and dextrocardia
Cryoballoon ablation of an arrhythmogenic focus alongside a pulmonary vein as an alternative to radiofrequency ablation may be feasible and safe in patients with situs inversus and dextrocardia.